PubMed Health⌕ Search

Biomedical subjects

L R Handlin

Publications and source records attributed to L R Handlin.

7 recordsLinked to original sources
PubMed1995

Gender-related differences in reperfusion treatment allocation and outcome for acute myocardial infarction.

Gender-related differences in outcome after myocardial infarction may relate to biased treatment allocation. To address this concern we analyzed 573 patients presenting with ST-segment elevation acute myocardial infarction (AMI), and treated within 6 hours with reperfusion therapy. Two-hundred eighty patients (49%) received direct coronary angioplasty, whereas 293 (51%) received thrombolytics followed by angioplasty (p = NS). Seventy-four percent were men and 26% were women (p = NS for differences in sex distribution between the 2 treatment groups). Women were older in both groups (p < 0.01). Inferior AMI was seen more often in women (64% of direct angioplasty, 71% of lytic first) than in men (51% and 59%, respectively; p < 0.03). There was no gender-related differences in presence of multivessel coronary artery disease, prior AMI, prior bypass surgery, baseline ejection fraction, percentage of patients with ejection fraction < or = 40%, number of narrowings dilated, or angioplasty success. Patients who underwent direct angioplasty had more multivessel disease (p < 0.001) and prior coronary artery bypass surgery (p = 0.002). After a mean follow-up of 129 +/- 113 weeks, no gender-related differences were seen in the need for cardiac catheterization, documented restenosis, AMI, coronary artery bypass surgery, clinical ischemia, or death. Patients treated with direct angioplasty were more likely to undergo coronary artery bypass surgery (p < 0.05) or to die (p < 0.01). Thus, women undergoing reperfusion therapy for ST-segment elevation were older than men, with a higher frequency of inferior wall AMI. No specific gender-related bias in treatment allocation was evident.

Aged↗
PubMed1995

Four- versus 6-minute infusion protocol for adenosine thallium-201 single photon emission computed tomography imaging.

Intravenous adenosine infusion results in immediate maximal coronary arteriolar vasodilatation. Side effects occur in most patients who receive adenosine. For these reasons, a shorter infusion for pharmacologic stress thallium-201 testing may improve patient tolerability without compromising diagnostic accuracy. In a retrospective, unblinded evaluation, we compared side effects and accuracy of a standard 6-minute adenosine infusion single photon emission computed tomography (SPECT) study with a 4-minute protocol in 730 and 621 patients, respectively. Adenosine was infused at 140 micrograms/kg/minute in both groups; thallium-201 was injected at the 3-minute mark of the 4-minute protocol and at the 4-minute mark of the 6-minute protocol. Angiographic follow-up (mean 8 days) after thallium-201 testing was available in 233 (32%) of the patients in the 6-minute protocol and in 174 (28%) of the patients in the 4-minute protocol (p not significant (NS). Side effects occurred in 90% of the patients in the 6-minute protocol and in 91% of the patients in the 4-minute protocol (p = NS). Premature termination of the infusion was required in 4% of the patients in the 6-minute protocol and 2% of the patients in the 4-minute protocol (p = 0.02). Second- or third-degree atrioventricular block was noted in 4.5% and 3.0% of the 6- and 4-minute groups, respectively (p = NS). The duration of symptoms averaged 2.9 +/- 4.4 minutes in the patients in the 6-min protocol and 2.1 +/- 1.6 minutes in the patients in the 4-minute protocol (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Adenosine↗
PubMed1994

Angioplasty versus thrombolysis for acute myocardial infarction.

Both direct angioplasty and thrombolytic therapy can decrease mortality from acute myocardial infarction, but certain subgroups of patients benefit more from one method than the other. Direct angioplasty is favored in patients in cardiogenic shock (with perhaps the exception of those who are elderly or have three-vessel coronary disease) and patients who have undergone previous coronary bypass surgery. Thrombolytic therapy and direct angioplasty seem to be equally effective in patients with acute myocardial infarction who present more than 6 hours after onset of symptoms or have multivessel coronary artery disease. The location of the infarct (anterior versus inferior) does not favor one therapy over the other. We believe that in most patients, the best approach is to begin with thrombolytic therapy and to follow that with selective application of angioplasty when it is clinically appropriate.

Aged↗
PubMed1994

Thrombolytic therapy for acute myocardial infarction. Are inclusion criteria too stringent?

There is little question that reperfusion therapy with thrombolytic agents benefits patients who meet the current eligibility requirements and receive therapy shortly after acute myocardial infarction. Less clear is whether this therapy would benefit and be safe for use in patients who are now deemed ineligible to receive it. The authors compare the three available intravenous thrombolytic agents, summarize the risks and benefits associated with thrombolytic therapy in various situations, and make recommendations based on their experience.

Anistreplase↗
PubMed1993

Effects of angiotensin-converting enzyme inhibitor therapy on presence of late potentials detected using signal-averaged electrocardiography in patients with congestive heart failure.

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors have been shown to improve the mortality rate in patients with congestive heart failure. The exact mechanism of this effect is uncertain. Signal-averaged electrocardiography has been used to evaluate the presence of late potentials as a marker for sudden cardiac death. We examined prospectively the effects of ACE inhibitor therapy on signal-averaged ECGs and ventricular arrhythmia frequency in 20 patients with moderate to severe left ventricular dysfunction and symptomatic congestive heart failure. METHODS: A signal-averaged ECG and 24 h Holter monitor were performed immediately before and both 1 week and 6 weeks after captopril initiation. The mean dose of captopril at 6 weeks was 38 +/- 31 mg. The patients (19 men and one woman, mean age 63 +/- 12 years) had a baseline ejection fraction of 22 +/- 7% and mean functional class of 2.6 +/- 0.5. The cause of congestive heart failure was coronary artery disease in 18 patients, idiopathic cardiomyopathy in one, and valvular disease in one. RESULTS: All three signal-averaged ECG time-domain parameters tended to improve over the course of the study (study 1, 2, 3: QRS duration (ms) = 108 +/- 11, 106 +/- 12, 105 +/- 11; low-amplitude signal duration (ms) = 30 +/- 8, 31 +/- 10, 28 +/- 10; root mean voltage (microV) = 33 +/- 20, 37 +/- 24, 40 +/- 2, respectively). These changes were not statistically significant, although the improvement in QRS duration was nearly so with P = 0.06. The occurrence and complexity of ventricular ectopy did not appear to be consistently altered. CONCLUSION: ACE inhibitor therapy with captopril did not appear to alter ventricular ectopy over the course of this study. However, the trends toward improvement of signal-averaged ECG parameters deserve further evaluation in a larger and longer-term study.

Action Potentials↗
PubMed1992

Slowing of ventricular tachycardia as a possible endpoint for serial drug testing at electrophysiological study.

Certain patients who cannot be rendered noninducible by serial drug testing during electrophysiology study demonstrate significant slowing of their ventricular tachycardia rate with selected agents. We evaluated the characteristics and outcome of 19 such patients to assess whether this slowing could be considered an acceptable endpoint for treatment. This group consisted of 14 males and 5 females (mean age 63 +/- 9) with a mean ejection fraction of 28 +/- 13% and inducible sustained ventricular tachycardia. Sixteen patients had known coronary artery disease and 13 had prior myocardial infarction. The other three patients had idiopathic cardiomyopathy. Serial drug testing during an electrophysiology protocol that used up to three extrastimuli at two or three cycle lengths at two right ventricular sites was used to select a medication regimen that provided optimal ventricular tachycardia slowing without limiting side effects. Five patients were treated with amiodarone, three with Ic agents (all with ejection fraction greater than 30%), and the remainder with Ia and Ib agents alone or in combination. Mean initial ventricular tachycardia rate was 219 +/- 26 beats/min with posttreatment ventricular tachycardia rate 137 +/- 17 (mean initial cycle length 278 +/- 35 msec, posttreatment 443 +/- 53 msec). Two groups were identified, those who had recurrent (although well-tolerated) ventricular tachycardia (group I, n = 8, mean time to recurrence = 15 months), and those who did not (group II, n = 11, mean follow-up 22 months). Overall sudden death rate was 5%, while total mortality was 11% (all mortality in group I).(ABSTRACT TRUNCATED AT 250 WORDS)

Amiodarone↗